Healthcare >> CEO Interviews >> June 2, 2004
RICHARD H. FRIEDMAN is Chairman and Chief Executive Officer of MIM
Corporation, a pharmaceutical healthcare organization. Mr. Friedman
joined MIM as Chief Operating and Financial Officer in 1996. He was
instrumental in taking the company public in August of 1996, an offering
that yielded $47 million. In May 1998, he assumed the role of Chief
Executive Officer and was elected Chairman of the Board of Directors.
Before joining MIM, Mr. Friedman served as the Chief Financial Officer
responsible for all finance, accounting and treasury functions for
Zenith Laboratories Inc., a leading manufacturer and distributor of
generic drugs. Under his guidance, Zenith reached its highest levels of
profitability. In connection with its financial success the company's
stock rose from approximately $11 per share to $90 per share from
1992-1994. Mr. Friedman was a leading member of the team that
orchestrated Zenith's sale to IVAX, yielding Zenith's shareholders in
excess of $600 million. Profile
Mr. Friedman: MIM Corporation is a pharmaceutical healthcare
organization that operates two business segments. One is specialty
pharmaceutical, which is the
